The aim of our study was to assess clinical features and treatment outcomes in ovarian cancer patients, having a founder mutation in BRCA1 gene in comparison with clinical results of sporadic ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.